Positions

Investigator On

  • Combination Anti-Amyloid Therapy for Preclinical Alzheimer's Disease  awarded by University of Southern California 2019 - 2024
  • UAB Alzheimer's Disease Research Center  awarded by National Institute on Aging/NIH/DHHS 2020 - 2023
  • The A3 Study: Ante-Amyloid Prevention of Alzheimer's Disease  awarded by University of Southern California 2019 - 2023
  • Private Grant  awarded by Genentech 2018 - 2022
  • Private Grant  awarded by BIOGEN MA INC 2018 - 2022
  • A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multicenter Study of Potential Disease Modifying Therapies in Individuals at Risk for and with Dominantly Inherited Alzheimer’s Disease (“Protocol”).  awarded by Washington University 2018 - 2022
  • Alzheimer's Disease Neuroimaging Initiative 3 (ADNl3)  awarded by University of Southern California 2016 - 2021
  • Private Grant  awarded by EISAI, INC. 2013 - 2021
  • Global Alzheimer’s Platform Trial-Ready Cohort for Preclinical/Prodromal Alzheimer’s Disease  awarded by University of Southern California 2019 - 2021
  • Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension Study  awarded by University of Southern California 2019 - 2020
  • Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease(A4 Study)  awarded by University of Southern California 2016 - 2020
  • A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of 2 Potential Disease Modifying Therapies in Individuals at Risk for and with Dominantly Inherited Alzheimer’s Disease  awarded by Washington University 2013 - 2020
  • Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study A Companion Observational Study to Antl-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial  awarded by University of Southern California 2016 - 2020
  • Private Grant  awarded by BIOGEN, INC. 2018 - 2020
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2016 - 2020
  • Private Grant  awarded by LILLY USA, LLC 2018 - 2020
  • Private Grant  awarded by ABBVIE INC 2018 - 2020
  • Private Grant  awarded by ABBVIE INC 2017 - 2020
  • A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multicenter Study of Potential Disease Modifying Therapies in Individuals at Risk for and with Dominantly Inherited Alzheimer’s Disease (“Protocol”)  awarded by THE WASHINGTON UNIVERSITY 2018 - 2020
  • Alzheimer's Disease Cooperative Study - A4 Study  awarded by University of Southern California 2017 - 2020
  • Private Grant  awarded by BIOGEN IDEC, INC. 2017 - 2020
  • Private Grant  awarded by BIOGEN, INC. 2016 - 2019
  • Private Grant  awarded by NEURIM PHARMACEUTICALS 2017 - 2019
  • The Frontotemporal Lobar Degeneration Clinical Research Consortium  awarded by University of California, San Francisco 2016 - 2019
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2017 - 2018
  • Exosome LRRK2 in Predicting Parkinson Disease Phenotypes  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2016 - 2018
  • Tau PET Imaging for the USC Alzheimer's Therapeutic Research Institute (USC ATRI) A4 Trial (“A4 TAU”)  awarded by University of Southern California 2017
  • Advancing Research and Treatment for Frontotemporal Lobar Degeneration [ARTFL]: Research Project 1 & 2  awarded by University of California, San Francisco 2015 - 2017
  • Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)  awarded by University of Southern California 2016 - 2017
  • Alzheimer's Disease Cooperative Study - A4 Study  awarded by University of Southern California 2015 - 2017
  • Education And Training

  • Doctor of Medicine, University of Alabama at Birmingham 2013
  • Full Name

  • Bryan Smelser